A Phase II Study of S-1 and Paclitaxel Combination Therapy as a First-Line Treatment in Elderly Patients with Advanced Non-Small Cell Lung Cancer

Yoshimura, Akihiro; Chihara, Yusuke; Date, Koji; Tamiya, Nanako; Takemura, Yoshizumi; Imabayashi, Tatsuya; Kaneko, Yoshiko; Yamada, Tadaaki; Ueda, Mikio; Arimoto, Taichiro; Uchino, Junichi; Iwasaki, Yoshinobu; Takayama, K.

doi:10.1634/theoncologist.2018-0858

Cited by 3 publications

(3 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We had previously conducted a phase I/II study of S‐1 and paclitaxel (PTX) combination therapy in previously untreated non‐small cell lung cancers among the elderly (≥70 years of age). In the phase II study at the recommended dose (RD; S‐1, 80 mg/m 2 ; PTX, 80 mg/m 2 ), the response and disease control rates were 53.3% and 93.3%, respectively, and the toxicities were mild . The present phase II study evaluated the efficacy and safety of S‐1 and PTX combination therapy after second‐line treatment in patients with previously treated NSCLC.…”

Section: Discussionmentioning

confidence: 95%

Phase II Study of S-1 and Paclitaxel Combination Therapy in Patients with Previously Treated Non-Small Cell Lung Cancer

et al. 2019

Self Cite

View full text Add to dashboard Cite

Lessons Learned. In terms of efficacy and safety, good results were obtained with S‐1 and paclitaxel (PTX) combination therapy. The findings suggest that S‐1 and PTX combination therapy is a feasible treatment option in patients with previously treated non‐small cell lung cancer. Background. Although monotherapy with cytotoxic agents, including docetaxel and pemetrexed, is recommended for patients with previously treated advanced non‐small cell lung cancer (NSCLC), its outcomes are unsatisfactory. S‐1 is an oral fluoropyrimidine agent that consists of tegafur, 5‐ chloro‐2, 4‐dihydroxypyridine, and potassium oxonate. S‐1 is approved for patients with gastric cancer in 7 Asian countries and 15 European countries. It is also approved for patients with eight type of cancers, including NSCLC, in Japan. We evaluated the efficacy and toxicity of S‐1 and paclitaxel (PTX) combination therapy in patients with previously treated NSCLC. Methods. Oral S‐1 was administered thrice weekly on days 1–14 at 80, 100, and 120 mg/day in patients with body surface areas of <1.25, 1.25–1.5, and >1.5 m 2 , respectively. PTX was administered at 80 mg/m 2 on days 1 and 8. Primary endpoint was response rate, and secondary endpoints were progression‐free survival (PFS), overall survival (OS), and safety. Results. Forty patients were enrolled, with response and disease control rates of 27.5% and 75.0%, respectively (Fig. 1). Median PFS and OS were 6.5 and 20.7 months, respectively. Grade 3/4 anemia and thrombocytopenia were seen in five (12%) and one (2%) patients, respectively. Febrile neutropenia occurred in three patients (7%). Common grade 3/4 nonhematological toxicities were stomatitis (5% of patients), diarrhea (7% of patients), and interstitial lung disease (one patient). No treatment‐related deaths were observed. Conclusion. This S‐1 and PTX cotherapy dose and schedule showed satisfactory efficacy, with mild toxicities, in patients with previously treated advanced NSCLC.

show abstract

Section: Discussionmentioning

confidence: 95%

Phase II Study of S-1 and Paclitaxel Combination Therapy in Patients with Previously Treated Non-Small Cell Lung Cancer

et al. 2019

Self Cite

View full text Add to dashboard Cite

show abstract

“…The dualfunctional theranostic photosensitizer (PS), TPCI, possesses a very high 1 O 2 quantum yield of ~99% in water and can simultaneously self-report the PDT therapeutic response from the beginning of the treatment [201]. TPCI along with a first-line chemotherapy agent (i.e., paclitaxel, PTX) [202][203][204] can be co-encapsulated in liposomes for a synergistic anticancer effect against a series of tumor cell lines, including those of prostate cancer. TPCI/PTX@Lipo (i.e., liposomes with TPCI and PTX) are spherical with an average size of 100-120 nm and encapsulation efficiency of 89% for PTX and 87% for TPCI.…”

Section: Prostate Cancermentioning

confidence: 99%

Liposomes for Cancer Theranostics

Fernandes

2023

Pharmaceutics

View full text Add to dashboard Cite

Cancer is one of the most well-studied diseases and there have been significant advancements over the last few decades in understanding its molecular and cellular mechanisms. Although the current treatments (e.g., chemotherapy, radiotherapy, gene therapy and immunotherapy) have provided complete cancer remission for many patients, cancer still remains one of the most common causes of death in the world. The main reasons for the poor response rates for different cancers include the lack of drug specificity, drug resistance and toxic side effects (i.e., in healthy tissues). For addressing the limitations of conventional cancer treatments, nanotechnology has shown to be an important field for constructing different nanoparticles for destroying cancer cells. Due to their size (i.e., less than 1 μm), nanoparticles can deliver significant amounts of cancer drugs to tumors and are able to carry moieties (e.g., folate, peptides) for targeting specific types of cancer cells (i.e., through receptor-mediated endocytosis). Liposomes, composed of phospholipids and an interior aqueous core, can be used as specialized delivery vehicles as they can load different types of cancer therapy agents (e.g., drugs, photosensitizers, genetic material). In addition, the ability to load imaging agents (e.g., fluorophores, radioisotopes, MRI contrast media) enable these nanoparticles to be used for monitoring the progress of treatment. This review examines a wide variety of different liposomes for cancer theranostics, with the different available treatments (e.g., photothermal, photodynamic) and imaging modalities discussed for different cancers.

show abstract

“…As a proof of concept, we co-encapsulated TPCI and paclitaxel (PTX), a first-line chemotherapy agent, − in liposomes composed of cholesterol and soy phosphatidylcholine (SPC) to enable a chemotherapy-potentiated photodynamic theranostics nanoagent “TPCI/PTX@Lipo” (Figure ). Markedly, TPCI/PTX@Lipo exhibited excellent synergism in killing a series of human carcinoma cells upon irradiation with significantly low combine index values.…”

Section: Introductionmentioning

confidence: 99%

Paclitaxel-Potentiated Photodynamic Theranostics for Synergistic Tumor Ablation and Precise Anticancer Efficacy Monitoring

Wang

Tong

et al. 2020

ACS Appl. Mater. Interfaces

View full text Add to dashboard Cite

Photodynamic theranostics that allows for concurrent photodynamic therapy (PDT) and precise therapeutic response report has emerged as an intriguing direction in the development of precision medicine. An ultra-efficient photodynamic theranostics platform was developed here based on combining and potentiating a theranostic photosensitizer, TPCI, with other therapies for synergistic anticancer effect and synchronous self-reporting of therapeutic response. In this study, TPCI and a chemotherapy agent paclitaxel (PTX) were co-encapsulated in liposomes, which exhibited a superb synergistic anticancer effect against a series of tumor cell lines. The potency of both drugs had been boosted for up to 30-fold compared with sole PDT or chemotherapy. More strikingly, the released TPCI lighted up the nuclei of dead cells, triggered either by PDT or chemotherapy, through binding with the chromatin and activating its aggregation-induced emission, therefore self-reporting the anticancer effect of the combined therapy in real time. The in vivo study using a mouse model bearing PC3 prostate tumor cells demonstrated the effective ablation of tumors with initial sizes of 200 mm3 and the precise early tumor response monitoring by TPCI/PTX@Lipo. This PTX-potentiated photodynamic theranostics strategy herein represented a new prototype of self-reporting nanomedicine for precise tumor therapy.

show abstract

A Phase II Study of S-1 and Paclitaxel Combination Therapy as a First-Line Treatment in Elderly Patients with Advanced Non-Small Cell Lung Cancer

Cited by 3 publications

References 23 publications

Phase II Study of S-1 and Paclitaxel Combination Therapy in Patients with Previously Treated Non-Small Cell Lung Cancer

Phase II Study of S-1 and Paclitaxel Combination Therapy in Patients with Previously Treated Non-Small Cell Lung Cancer

Liposomes for Cancer Theranostics

Paclitaxel-Potentiated Photodynamic Theranostics for Synergistic Tumor Ablation and Precise Anticancer Efficacy Monitoring

Contact Info

Product

Resources

About